Xifaxan He denied for failing step therapy by Cigna?

Cigna's specific coverage criteria for xifaxan he are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Applied a Step-Therapy Requirement

A step-therapy denial for rifaximin (Xifaxan) for hepatic encephalopathy (HE) means Cigna requires documentation that you have first tried one or more "preferred" or lower-cost alternative treatments before it will authorize rifaximin. In the HE context, the required step is most commonly lactulose. If Cigna's records do not show a prior trial of the required agent — with documented outcomes — the authorization will be denied regardless of how appropriate rifaximin is for your case.

This is a process-driven denial, not a judgment that rifaximin is wrong for you. It is entirely correctable when the clinical record reflects the required step, or when your physician documents a clinical reason the step cannot safely be taken.

## Why This Is Appealable

• Completed-step exception: If you have already tried the required prior agent and it failed, was inadequate, or caused unacceptable side effects, you are entitled to an exception — Cigna's records may simply not reflect that history.
• Contraindication or clinical bypass: If your prescriber determines that the required step therapy agent is clinically inappropriate for your specific presentation, that judgment — documented in the chart — can support a step-therapy exception.
• State step-therapy laws: Many states have enacted laws requiring insurers to grant exceptions to step-therapy protocols when specific clinical criteria are met. Check whether your state's law applies to your plan type.
• ACA §2719 external review: After internal appeals are exhausted, an independent external reviewer evaluates whether Cigna's step-therapy requirement was reasonable as applied to you. You generally have approximately four months from the denial notice; verify the deadline on your EOB.
• ERISA §503: The plan must disclose the step-therapy criteria and allow clinical rebuttal.
• Expedited review: Available if delay would seriously jeopardize your health.

## Documentation to Gather

• Prior-treatment history with dates and outcomes: A dated, chronological record of every HE treatment previously tried — most importantly the required step agent — documenting when it was started, stopped, and what the clinical outcome was (inadequate response, side effects, contraindication).
• Prescriber step-therapy exception letter: Your physician should explain either that the required step has been completed (with documented outcomes) or that it is clinically inappropriate for you, with the specific clinical reasoning.
• Diagnosis and severity records: Supporting chart documentation confirming HE diagnosis and disease course.
• Cigna's step-therapy policy: Download the policy from Cigna's website. Confirm each required step is addressed in your documentation.

## Criteria-Mapping Approach

Obtain Cigna's step-therapy criteria for rifaximin-HE. List each required step. For each, provide the chart-documented date of trial, clinical outcome, and — if that step was not taken — your prescriber's written clinical rationale for bypassing it. This one-to-one mapping is the difference between a successful exception request and a generic appeal letter that leaves gaps for reviewers to deny.